Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — Organic / Comparable Sales Growth (%) (%)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, Q3 2026
13.8%
Period ended Sep 30, 2026
Change on a year earlier
–
History
3 quarters
Since Q1 2026
Sources
3
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — Organic / Comparable Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 13.8% | – | SEC Filing (0001628280-26-066601) ↗ |
| Q2 2026 | Jun 30, 2026 | 13.3% | – | SEC Filing (0001628280-26-048377) ↗ |
| Q1 2026 | Mar 31, 2026 | 13.4% | – | SEC Filing (0001628280-26-025365) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — Organic / Comparable Sales Growth (%) (%), quarterly Q1 2026–Q3 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-cancer-yoy-org
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.